Trial
NCT04978337
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Respiratory Syncytial Virus
Intervention
Rilematovir
Why stopped
Janssen made the strategic decision to discontinue the PRIMROSE study. This decision is not based on any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-24